Using whole-exome sequencing, the <i>STAT3</i> (c.1294G>T, p.Val432Leu) missense mutation for the autosomal dominant hyper-IgE syndrome was identified, and omalizumab was prescribed at 300 mg every 2 weeks. This evidence concerns the gene STAT3 and Autosomal dominant hyper-IgE syndrome.